Using a Novel, Subconjunctival, Sustained-Release Mitomycin C Formulation in a Rabbit Model of Filtration Surgery with Gel Stent Implantation
Journal of Ocular Pharmacology and Therapeutics · 01.06.2024 · 40 (5) · 297-308
DOI: 10.1089/jop.2023.0100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, online erschienen am 17.06.2024. Verfasst von Susan S Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Allergan, an AbbVie company, Irvine, California, USA. Hauptthemen laut MEDLINE: Mitomycin, Delayed-Action Preparations, Filtering Surgery, Intraocular Pressure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To investigate gel stent implantation with and without intraoperative sustained-release mitomycin C (MMC SR) in a rabbit model for gel stent implantation, and to examine aqueous humor outflow (AHO) postimplantation.
Methods
Four groups of rabbits were included. Group 1 was untreated (control). Groups 2, 3, and 4 received the gel stent without MMC, with MMC solution (subconjunctival injection), and with MMC SR (subconjunctival injection), respectively. Intraocular pressure (IOP) and AHO were assessed via tonometry and indocyanine green-based angiography, respectively. The main efficacy measure was change in IOP from baseline.
Results
Following gel stent implantation, Groups 2, 3, and 4 maintained ≥20% IOP reduction (response) for a median duration of 1 week, 6.5 weeks, and 30 weeks, respectively. Angiography showed normal aqueous humor drainage (Group 1) beginning at the perilimbal trabecular plexus and continuing posteriorly to episcleral outflow vessels. Following implantation, drainage occurred preferentially and directly into the subconjunctival bleb.
Conclusions
Gel stent implantation with MMC SR was most effective in achieving sustained, long-term IOP reduction in the rabbit model, compared with implantation with or without MMC solution. Bleb presence and the postimplantation aqueous angiography results indicated redirection of the AHO to the subconjunctival vasculature and presumed lymphatics, suggesting efficient glaucoma filtration to lower IOP in this model. This rabbit model and aqueous angiography may help refine understanding of the mechanism of action of minimally invasive glaucoma surgeries and ultimately translate to improved surgical devices and procedures for patients with glaucoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergan, an AbbVie company, Irvine, California, USA.
- Retina Foundation of the Southwest, Dallas, Texas, USA.
Zitieren
APA
Lee, S. S., Nagar, S., Rajagopalan, L., Orilla, W., Csaky, K. G., Almazan, A., Yang, L., & Robinson, M. R. (2024). Using a Novel, Subconjunctival, Sustained-Release Mitomycin C Formulation in a Rabbit Model of Filtration Surgery with Gel Stent Implantation. Journal of Ocular Pharmacology and Therapeutics, 40(5), 297-308. https://doi.org/10.1089/jop.2023.0100
Vancouver
Lee SS, Nagar S, Rajagopalan L, Orilla W, Csaky KG, Almazan A, et al. Using a Novel, Subconjunctival, Sustained-Release Mitomycin C Formulation in a Rabbit Model of Filtration Surgery with Gel Stent Implantation. Journal of Ocular Pharmacology and Therapeutics. 2024;40(5):297-308. doi:10.1089/jop.2023.0100
BibTeX
@article{Lee2024,
author = {Lee, Susan S and Nagar, Saumya and Rajagopalan, Lakshmi and Orilla, Werhner and Csaky, Karl G and Almazan, Alexandra and Yang, Liuqing and Robinson, Michael R},
title = {Using a Novel, Subconjunctival, Sustained-Release Mitomycin C Formulation in a Rabbit Model of Filtration Surgery with Gel Stent Implantation},
journal = {Journal of Ocular Pharmacology and Therapeutics},
year = {2024},
volume = {40},
number = {5},
pages = {297--308},
doi = {10.1089/jop.2023.0100}
}
EUVIMED